Aktis Oncology, Inc. Common stock (AKTS) Earnings

AKTS Earnings Reports

Positive Surprise Ratio

AKTS beat 1 of 3 last estimates.

33%

Next Report

Date of Next Report

Estimate for Q-- -- (Revenue/ EPS)

Implied change from Q2 26 (Revenue/ EPS)

Implied change from Q-- -- (Revenue/ EPS)

Aktis Oncology, Inc. Common stock earnings per share and revenue

On Aug 13, 2026, AKTS reported earnings of -0.44 USD per share (EPS) for Q2 26, missing the estimate of -0.43 USD, resulting in a -1.34% surprise. Revenue reached 3.38 million, compared to an expected 2.04 million, with a 65.88% difference. The market reacted with a +4.79% price change (close before vs. close after earnings).

Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

FAQ

What were Aktis Oncology, Inc. Common stock's earnings and revenue for the latest quarter Q2 2026?

For Q2 2026, Aktis Oncology, Inc. Common stock reported EPS of -$0.44, missing estimates by -1.34%, and revenue of $3.38M, 65.88% above expectations.

How did the market react to Aktis Oncology, Inc. Common stock's Q2 2026 earnings?

The stock price moved up 4.79%, changed from $23.79 before the earnings release to $24.93 the day after.

When is Aktis Oncology, Inc. Common stock expected to report next?

The next earning report is scheduled for --.

What are the forecasts for Aktis Oncology, Inc. Common stock's next earnings report?

Based on -- analysts, Aktis Oncology, Inc. Common stock is expected to report EPS of -- and revenue of -- for Q-- --.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.